Free Trial
OTCMKTS:BTCY

Biotricity Q1 2025 Earnings Report

Biotricity logo
$0.63 +0.09 (+16.74%)
As of 08/15/2025 03:34 PM Eastern

Biotricity EPS Results

Actual EPS
-$0.49
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biotricity Revenue Results

Actual Revenue
$3.20 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biotricity Announcement Details

Quarter
Q1 2025
Time
N/A
Conference Call Date
Wednesday, August 21, 2024
Conference Call Time
2:00AM ET

Biotricity Earnings Headlines

New law could create $3.7 trillion tsunami.
During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.
Rogue Funds’ New Holding: Biotricity (BTCY)
See More Biotricity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biotricity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biotricity and other key companies, straight to your email.

About Biotricity

Biotricity (OTCMKTS:BTCY), Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

View Biotricity Profile

More Earnings Resources from MarketBeat